Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition

Fig. 3

ABBV-176 is active in combination in vivo with the PARP inhibitor Veliparib. Mice with CTG-0670 breast cancer PDX tumors were treated with a single dose of 0.1 mg/kg ABBV-176, 0.1 (−)Co-PBD mg/kg, vehicle, or Veliparib BID × 21 days, or a combination of each ADC with Veliparib at the same amount and schedule (groups of n = 10) (A). Mice with HuH-7 LOT HCC tumors were treated Q7D × 3 with either 0.2 mg/kg ABBV-176, 0.2 (−)Co-PBD mg/kg, vehicle, or Veliparib BID × 21 days, or a combination of one ADC with Veliparib at the same amount and schedule (groups of n = 9). (B)

Back to article page